Sergio Bracarda

List of Publications by Year
in descending order

148 papers	18,885 citations	66315 42 h-index	11928 134 g-index
157 all docs	157 docs citations	157 times ranked	16444 citing authors

#	Article	IF	Citations
1	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
2	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, The, 2008, 372, 449-456.	6.3	2,848
3	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, The, 2007, 370, 2103-2111.	6.3	2,140
4	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2017, 18, 312-322.	5.1	1,388
5	Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer, 2010, 116, 4256-4265.	2.0	1,039
6	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	15.2	900
7	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	6.3	778
8	Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. Journal of Clinical Oncology, 2010, 28, 2144-2150.	0.8	767
9	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	5.1	594
10	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncology, The, 2009, 10, 757-763.	5.1	571
11	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research, 2019, 25, 928-936.	3.2	232
12	Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. European Urology, 2012, 61, 11-25.	0.9	206
13	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1599-1611.	5.1	181
14	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet, The, 2021, 398, 131-142.	6.3	167
15	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology, 2018, 36, 578-578.	0.8	164
16	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
17	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 2014, 50, 1617-1627.	1.3	133
18	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	1.9	131

#	Article	IF	Citations
19	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 2011, 117, 501-509.	2.0	126
20	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
21	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology, 2018, 36, 765-772.	0.8	117
22	Predictive Factors of Delayed Emesis in Cisplatin-Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or Dexamethasone. American Journal of Clinical Oncology: Cancer Clinical Trials, 1991, 14, 238-242.	0.6	106
23	Cancer of the prostate. Critical Reviews in Oncology/Hematology, 2005, 56, 379-396.	2.0	89
24	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. European Journal of Cancer, 2014, 50, 1090-1099.	1.3	88
25	Redefining the role of interferon in the treatment of malignant diseases. European Journal of Cancer, 2010, 46, 284-297.	1.3	85
26	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	1.3	85
27	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	1.3	81
28	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	5.1	73
29	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72
30	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: realâ€world results from an expanded access programme. BJU International, 2019, 123, 98-105.	1.3	70
31	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. PLoS ONE, 2013, 8, e83026.	1.1	66
32	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	3.5	65
33	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. European Journal of Cancer, 2016, 69, 226-235.	1.3	65
34	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. European Urology, 2021, 79, 659-662.	0.9	64
35	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	5.1	61
36	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. European Urology, 2012, 61, 826-833.	0.9	59

#	Article	IF	Citations
37	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58
38	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews, 2017, 55, 71-82.	3.4	56
39	CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors. BioMed Research International, 2014, 2014, 1-12.	0.9	51
40	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	1.7	49
41	Patients with sarcomatoid renal cell carcinoma â€“ re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. European Journal of Cancer, 2020, 136, 195-203.	1.3	47
42	Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. European Journal of Cancer, 2015, 51, 1293-1302.	1.3	45
43	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	1.3	45
44	PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT).. Journal of Clinical Oncology, 2012, 30, 4541-4541.	0.8	45
45	Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies. Seminars in Oncology, 2015, 42, 495-505.	0.8	44
46	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferonâ€Î±2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU International, 2011, 107, 214-219.	1.3	43
47	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncology, 2014, 10, 975-983.	1.1	43
48	The medical management of prostate cancer: a multidisciplinary team approach. BJU International, 2007, 99, 22-27.	1.3	36
49	Current and emerging treatment modalities for metastatic castrationâ€resistant prostate cancer. BJU International, 2011, 107, 13-20.	1.3	35
50	Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma. , 2000, 88, 1438-1444.		30
51	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY). European Urology, 2013, 63, 254-261.	0.9	29
52	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Targeted Oncology, 2020, 15, 495-501.	1.7	28
53	Pros-IT CNR: an Italian prostate cancer monitoring project. Aging Clinical and Experimental Research, 2017, 29, 165-172.	1.4	26
54	Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group. Critical Reviews in Oncology/Hematology, 2012, 82, 378-386.	2.0	25

#	Article	IF	Citations
55	Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. Oncology, 2015, 88, 273-280.	0.9	24
56	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health and Quality of Life Outcomes, 2018, 16, 122.	1.0	24
57	Predictive ability of a drug-based score in patients with advanced nonâ€“small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	1.3	24
58	A Double-Blind Trial Comparing Antiemetic Efficacy and Toxicity of Metoclopramide Versus Methylprednisolone Versus Domperidone in Patients Receiving Doxorubicin Chemotherapy Alone or in Combination with Other Antiblastic Agents. American Journal of Clinical Oncology: Cancer Clinical Trials, 1988, 11, 594-596.	0.6	23
59	Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. ESMO Open, 2020, 5, e000652.	2.0	23
60	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer, 2021, 19, e84-e91.	0.9	23
61	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	1.7	22
62	Targeting of EGFR tyrosine kinase by ZD1839 (â€œIressaâ€) in androgen-responsive prostate cancer in vitro. Molecular Genetics and Metabolism, 2006, 88, 114-122.	0.5	20
63	Poor Survival in Prostate Cancer Patients with Primary Refractoriness to Docetaxel. European Urology, 2014, 65, 505-507.	0.9	20
64	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Frontiers in Oncology, 2019, 9, 228.	1.3	20
65	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.4	20
66	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. Prostate Cancer and Prostatic Diseases, 2020, 23, 199-206.	2.0	20
67	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-NaÃ¯ve Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2506-2514.	3.2	20
68	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. European Urology, 2021, 79, 665-673.	0.9	20
69	Patientâ€reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU International, 2020, 126, 73-82.	1.3	19
70	Post-progression outcomes of NSCLC patients with PD-L1 expression â‰¥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	1.3	19
71	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials. BMC Cancer, 2010, 10, 675.	1.1	18
72	GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 386-393.	2.0	18

#	Article	IF	Citations
73	How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2017, 17, 227-233.	1.1	18
74	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. European Urology Focus, 2022, 8, 1696-1702.	1.6	17
75	Safety of Everolimus by Treatment Duration inÂPatients With Advanced Renal Cell Cancer in an Expanded Access Program. Urology, 2013, 81, 143-149.	0.5	16
76	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. European Urology Focus, 2017, 3, 321-324.	1.6	15
77	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	2.0	15
78	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2020, 18, 477-488.	0.9	15
79	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. Critical Reviews in Oncology/Hematology, 2015, 93, 50-59.	2.0	14
80	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	14
81	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096846.	1.4	14
82	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	1.8	14
83	Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer. Lung Cancer, 2002, 37, 79-85.	0.9	13
84	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. Diagnostics, 2021, 11, 138.	1.3	13
85	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	13
86	IGG* Practice Guidelines on Germ Cell Tumor in Adult Male Patients. Tumori, 2008, 94, 96-109.	0.6	12
87	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncology, 2014, 10, 1741-1750.	1.1	12
88	Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. Clinical Genitourinary Cancer, 2019, 17, e689-e703.	0.9	12
89	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. BMC Cancer, 2019, 19, 283.	1.1	12
90	Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database. Scientific Reports, 2021, 11, 7150.	1.6	12

#	Article	IF	Citations
91	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 4511-4511.	0.8	12
92	Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Expert Review of Anticancer Therapy, 2014, 14, 1283-1294.	1.1	11
93	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	2.0	11
94	Ondansetron. European Journal of Cancer, 1993, 29, S16-S21.	1.3	10
95	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. Critical Reviews in Oncology/Hematology, 2019, 139, 149-157.	2.0	10
96	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2019, 105, 3-12.	0.6	10
97	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the) Tj ETQq1 1 0.784314 rgBT /Overlock 2020, 72, 595-604.	3.9	10
98	Mechanism of 2-chloroadenosine toxicity to PC3 cell line. Prostate, 2006, 66, 1425-1436.	1.2	9
99	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews, 2012, 38, 127-132.	3.4	9
100	Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opinion on Drug Safety, 2014, 13, 497-510.	1.0	9
101	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clinical Genitourinary Cancer, 2014, 12, 262-269.	0.9	9
102	Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule. Frontiers in Pharmacology, 2017, 8, 523.	1.6	9
103	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. Future Oncology, 2018, 14, 1347-1354.	1.1	9
104	Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. OncoImmunology, 2020, 9, 1710389.	2.1	9
105	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation. Future Oncology, 2015, 11, 3083-3090.	1.1	8
106	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clinical Genitourinary Cancer, 2016, 14, 406-414.	0.9	8
107	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. Critical Reviews in Oncology/Hematology, 2018, 125, 51-59.	2.0	8
108	Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. Oncotarget, 2019, 10, 4161-4168.	0.8	8

#	Article	IF	Citations
109	Reliability and validity of a quality of life questionnaire in cancer patients. European Journal of Cancer, 1993, 29, S63-S69.	1.3	7
110	The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance. International Journal of Molecular Sciences, 2017, 18, 1512.	1.8	7
111	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. Journal of Clinical Pathology, 2022, 75, 39-44.	1.0	7
112	Laparoscopic Compared with Open D2 Gastrectomy on Perioperative and Long-Term, Stage-Stratified Oncological Outcomes for Gastric Cancer: A Propensity Score-Matched Analysis of the IMIGASTRIC Database. Cancers, 2021, 13, 4526.	1.7	6
113	Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. Clinical and Translational Imaging, 2021, 9, 215-220.	1.1	5
114	Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. Minerva Urology and Nephrology, 2022, 74, .	1.3	5
115	2â€Chloroadenosine modulates PARâ€1 and ILâ€23 expression and enhances docetaxel effects on PC3 cells. Prostate, 2008, 68, 360-372.	1.2	4
116	Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape. European Urology Supplements, 2009, 8, 787-792.	0.1	4
117	Current and Future Treatment Options for Metastatic Renal Cell Carcinoma. European Urology Supplements, 2009, 8, 799-808.	0.1	4
118	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers, 2022, 14, 2293.	1.7	4
119	Prostate changes related to therapy: with special reference to hormone therapy. Future Oncology, 2014, 10, 1873-1886.	1.1	3
120	REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis. Future Oncology, 2015, 11, 2893-2903.	1.1	3
121	Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused. European Urology, 2015, 67, 680-681.	0.9	3
122	Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastases survey.. Journal of Clinical Oncology, 2012, 30, 4627-4627.	0.8	3
123	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 253-253.	0.8	3
124	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Therapeutic Advances in Urology, 2021, 13, 175628722110543.	0.9	3
125	Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.. Journal of Clinical Oncology, 2013, 31, 356-356.	0.8	3
126	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	1.1	3

#	Article	IF	Citations
127	Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. Clinical Genitourinary Cancer, 2022, 20, 498.e1-498.e9.	0.9	3
128	Antiemetic Activity of Two Different High Doses and Schedules of Metoclopramide in Dacarbazine-Treated Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 1992, 15, 112-114.	0.6	2
129	Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma. European Urology Supplements, 2009, 8, 815-819.	0.1	2
130	Biologic tools to personalize treatment in genitourinary cancers. Critical Reviews in Oncology/Hematology, 2012, 84, e42-e48.	2.0	2
131	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. Critical Reviews in Oncology/Hematology, 2016, 98, 254-263.	2.0	2
132	Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societiesâ€™ agenda. Tumori, 2019, 105, 161-167.	0.6	2
133	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer, 2020, 6, 43-52.	0.2	2
134	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. Cancers, 2019, 11, 1908.	1.7	1
135	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	1.3	1
136	The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study. Minerva Urology and Nephrology, 2022, 74, .	1.3	1
137	Editorial Comment on: Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study. European Urology, 2007, 52, 1698-1699.	0.9	0
138	Editorial Comment on: Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. European Urology, 2008, 53, 331.	0.9	0
139	Editorial Comment. Journal of Urology, 2017, 198, 536-537.	0.2	0
140	â€œTo Cut or Not to Cutâ€, a Biomolecular Approach to Metastasectomy in Metastatic Clear Cell Renal Cell Carcinoma. European Urology, 2018, 74, 481-482.	0.9	0
141	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	1.2	0
142	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology, 2012, 30, e15112-e15112.	0.8	0
143	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. Journal of Clinical Oncology, 2013, 31, 189-189.	0.8	0
144	Retrospective analysis of sorafenib as first or second target therapy in mRCC patients in Italian centers: An update.. Journal of Clinical Oncology, 2013, 31, e15524-e15524.	0.8	0

#	Article	IF	Citations
145	Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).. Journal of Clinical Oncology, 2013, 31, e16093-e16093.	0.8	0
146	New Frontiers in Treatment. , 2017, , 209-221.		0
147	No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases. Annals of Translational Medicine, 2019, 7, 612-612.	0.7	0
148	Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P. Advances in Respiratory Medicine, 2022, 90, 234-235.	0.5	0